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Many currently available inactivated vaccines require “adjuvants” to maximize the protec-
tive immune responses generated against the antigens of interest. Recent studies in mice
with gamma-irradiated influenza A virus (γ-FLU) have shown its superior efficacy compared
to other forms of inactivated FLU vaccines and its ability to induce both potent interferon
type-I (IFN-I) responses and the IFN-I-associated partial lymphocyte activation. Commonly,
IFN-I responses induced by adjuvants, combined in vaccine preparations, have been shown
to effectively enhance the immunogenicity of the antigens of interest.Therefore, we investi-
gated the potential adjuvant activity of γ-FLU and the possible effect on antibody responses
against co-administrated antigens, using gamma-irradiated Semliki Forest virus (γ-SFV) as
the experimental vaccine in mice. Our data show that co-vaccination with γ-FLU and γ-SFV
resulted in enhanced SFV-specific antibody responses in terms of increased titers by six-
fold and greater neutralization efficacy, when compared to vaccination with γ-SFV alone.
This study provides promising evidence related to the possible use of γ-FLU as an adjuvant
to poorly immunogenic vaccines without compromising the vaccine efficacy of γ-FLU.
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INTRODUCTION
Vaccines represent a fundamental aspect of current control strate-
gies against infectious diseases. However, despite the remarkable
success of many vaccines, there still remains many challenges in
the field of vaccinology, such as generating effective vaccination
strategies against notoriously difficult pathogens like hepatitis C
virus and human immunodeficiency virus (1). Among the vari-
ous types of currently used vaccines, live attenuated vaccines can
mimic natural infections and consequently have been shown to
be very effective in generating long-lived immunity. However,
due to the high risk of conversion to their highly pathogenic
form and the inability to develop live attenuated vaccines for
many pathogens, inactivated vaccines such as inactivated whole
viruses and purified antigens have typically been used as the main
strategy for vaccine design. However, poor immunogenicity of
many inactivated vaccines has severely affected their effective-
ness. Therefore, inactivated vaccines often require “adjuvants” to
enhance their immunogenicity. Importantly, most immunostim-
ulatory adjuvants have been designed to potently stimulate innate
signaling pathways through pattern recognition receptors (PRR)
such as toll-like receptors (TLR) and cytosolic receptors (2–5).
This ultimately leads to the induction of genes encoding for var-
ious immune-modulatory molecules including interferon type-I
(IFN-I), which stimulate co-stimulatory molecule expression and
antigen presentation (6).
Currently in vaccine design, greater attention is being drawn
toward designing adjuvants to effectively boost the immune
response toward existing vaccine preparations, which fail to
induce sufficient immunity. The influence of IFN-I exogenously
or through PRR stimulation has been shown to be very effective
(7–9). We have previously reported the superiority of gamma-
irradiated influenza virus (γ-FLU), compared to other flu vac-
cine formulations, in terms of inducing cross-protective immu-
nity (10–12). We have also shown that γ-FLU similarly to
its live form is capable of inducing potent IFN-I responses
and the associated partial lymphocyte activation 24 h post-
challenge (13, 14). Importantly, in contrast to gamma-irradiation
of influenza, we have shown that gamma-irradiation of Sem-
liki Forest virus (SFV) abrogates its ability to induce IFN-I
responses (15). Therefore, we investigated the potential adju-
vant activity of γ-FLU on co-administered γ-SFV as an experi-
mental model for poor immunogenic vaccines. Here, we report
that co-vaccination with γ-FLU and γ-SFV resulted in enhanced
SFV-specific antibody titers “by six-folds” when compared to
vaccination with γ-SFV alone. This enhancement in antibody
titer was also associated with greater SFV neutralization effi-
cacy and importantly; the vaccine efficacy of γ-FLU was not
affected.
MATERIALS AND METHODS
ETHICS STATEMENT
This study was carried out in strict accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of The University of Adelaide. The protocol was approved by the
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Animal Ethics Committee at The University of Adelaide (Permit
Number: S-2011/119).
VIRUSES AND CELLS
Avirulent SFV (A7 strain) was grown in vitro by infecting Vero
cells using multiplicity of infection (MOI) of 0.1, and infected
flasks were incubated for 24 h at 37°C in a humidified atmosphere
with 5% CO2. Culture supernatants were then collected and clar-
ified to remove cellular debris by centrifugation at 1500 rpm for
5 min. Virus titer was determined by plaque assay on Vero cells to
be 3× 108 PFU/ml. For the vaccine preparation, SFV stock was
concentrated using Millipore filtering devices with 100 kDa cut-
off (Millipore) and centrifugation at 2000 rpm for 1 h at 4°C using
Eppendorf bench top centrifuge. Virus titer of the concentrated
SFV was determined by plaque assay on Vero cells to be 5× 108
PFU/ml.
The influenza type A virus, A/PR/8 [(A/Puerto Rico/8/34
(H1N1)], was grown in 10-day-old embryonated chicken eggs
(HiChick, SA, Australia). Each egg was injected with 0.1 ml nor-
mal saline containing 1 hemagglutination unit (HAU) of virus,
incubated for 48 h at 37°C, and then held at 4°C overnight. The
amniotic/allantoic fluids were then harvested, pooled, clarified,
and stored at −80°C. Gamma-irradiated A/PR8 vaccine prepa-
rations were previously prepared by Dr. Furuya at ANU. Briefly,
concentrated virus stocks were prepared using chick erythrocytes
as previously described (16). Infectious allantoic fluid was incu-
bated with chicken red blood cells (cRBCs) for 45 min at 4°C
allowing the hemagglutinin to bind to erythrocytes, and then
centrifuged (4°C, 1500 rpm, 10 min) to remove the allantoic fluid
supernatant. The pellets were resuspended in normal saline, incu-
bated for 1 h at 37°C to release the RBCs from the virus, and then
centrifuged to remove the erythrocytes and the supernatant con-
taining the virus collected. The titer of the concentrated A/PR8
virus stock (9× 108 TCID50/ml) was determined by TCID50
assay (17).
VIRUS INACTIVATION
Concentrated virus stocks were inactivated by exposure to gamma-
irradiation from a 60Co source [Australian Nuclear Science
and Technology Organization (ANSTO) at Lucas Heights/NSW].
A/PR8 and SFV received a dose of 10 and 50 kGy, respectively,
and they were kept frozen on dry ice during gamma-irradiation.
Sterility was tested by two independent methods: plaque assay
using MDCK (for A/PR8) or Vero cells (for SFV); and by inoc-
ulating embryonated eggs (for A/PR8). The detection limit of
our plaque assay is 10 PFU/ml and no plaque forming unit was
detected for the irradiated samples. These tests confirmed sterility
of inactivated stocks. In addition, we have estimated the minimum
inoculum required to cause a positive infection in embryonated
eggs and found that the minimum egg infectious dose that causes
detectable HA titers in the allantoic fluid after 2 days of incuba-
tion is 0.1 TCID50/egg. Embryonated eggs were inoculated with
100 ml of inactivated preparations per egg and incubated for 2 days
at 37°C and the allantoic fluid of individual eggs was harvested and
tested for virus replication using HA assays. HA titers were nega-
tive in the allantoic fluid of these eggs, which illustrates a complete
loss of virus infectivity in our inactivated preparations.
MICE AND TREATMENTS
Wild-type C57B/6 mice (9–10-week-old) were bred under specific
pathogen-free conditions and supplied by the Animal Laboratory
Services at the University of Adelaide, SA, Australia.
In general, vaccine preparations were diluted using 10-fold ser-
ial dilutions and each mouse was injected in the tail vein with
200µl of the relevant virus or vaccine preparation. The follow-
ing doses were used: live SFV (107 PFU/mouse), γ-SFV (either
106, 107, or 108 PFU equivalent/mouse), and γ-FLU (104, 105
TCID50 equivalent/mouse). Refer to text for specific doses used
in each experiment. For co-vaccination, the two vaccine prepara-
tions were mixed thoroughly in the same tube and administered as
a single injection into experimental animals. Vaccination doses are
expressed PFU or TCID50 equivalent. In addition, in some exper-
iments Poly(I:C) was injected intravenously at a dose of 150µg in
200µl of PBS per animal as previously reported (18).
ANTIBODY ANALYSIS
Semliki Forest virus-specific and FLU-specific antibody responses
in serum samples were determined by enzyme-linked immunosor-
bent assay (ELISA). In brief, Maxisorp plates were coated with
concentrated SFV or FLU viral antigen diluted in bicarbonate
coating buffer (Na2CO3, NaHCO3, water at pH 9.6) and incubated
overnight at room temperature. Non-specific protein binding sites
were then blocked with PBS containing 2% skim milk powder
for 2 h at room temperature. Fifty microliter volumes of serially
diluted serum samples were added to the appropriate wells for
2 h at room temperature followed by the addition of horse radish
peroxidase conjugated goat anti-mouse IgG (Thermo Scientific)
at room temperature for 2 h. Plates were developed using TMB
peroxidase substrate in the dark for 30 min and the reaction was
stopped with 2 mol H2SO4. Absorbance was measured at 450 nm
using a Microplate ELISA reader (Bio-Tek Instruments).
NEUTRALIZATION ASSAYS
Plaque reduction assay modified from (19) was used to analyze
SFV neutralization. Twenty-four well tissue culture plates were
seeded with 1.5× 105 Vero cells/well and incubated overnight
at 37°C in a humidified atmosphere with 5% CO2. Aliquots of
serum samples from control and vaccinated animals were incu-
bated at 56°C for 30 min to inactivate complements and serially
diluted using EMEM media without FCS. Diluted samples were
mixed with equivalent amount of DMEM media containing 100
PFU of SFV. Mixtures (sera and virus) were incubated for 1.5 h at
37°C and then used to infect confluent Vero cell monolayer’s (in
triplicate) prepared earlier. Initially, culturing media was removed
from each well prior to addition of virus/serum mixture. Plates
were then incubated for 2 h at 37°C to allow infection of mono-
layers. Following incubation, the infecting mixture was removed
and an agar overlay containing 50% of 1.8% Bacto-Agar, 40%
DMEM media, 10% FCS, and 0.002% Fungizone was added to
each well and plates were incubated for 3 days at 37°C, 5% CO2.
Following incubation, cells were fixed with 5% formalin for 1 h at
room temperature. The overlay was then carefully removed and
cell monolayers were stained with 0.2% crystal violet. Plaques
were enumerated to determine the effect of the serum on virus
infectivity.
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FIGURE 1 | γ-SFV vaccine induces protective antibody responses.
(A) Mice were injected i.v. with SFV (107 PFU) or variable doses of γ-SFV
(106, 107, or 108 PFU equivalent/mouse). Twenty days post-injection,
serum SFV-specific IgG levels were measured by direct ELISA using a
serum dilution of 1/200. Serum from naive mice served as the negative
control. (B) Mice were vaccinated i.v. with γ-SFV (107 PFU
equivalent/mouse) and challenged 14 days post-vaccination with SFV
(107 PFU). Twenty four hours post-challenge, serum SFV titers were
determined by plaque assay. Un-vaccinated naive mice infected with
SFV served as control. Results are presented as mean±SEM (n=3)
and dashed line represents our assay detection limit of 100 PFU,
***p<0.001.
In addition, a hemagglutination inhibition assay (HAI) was
used to test the influenza-specific antibody responses, as previ-
ously described (17). Aliquots of sera were incubated at 56°C to
inactivate complements for 30 min, then diluted in PBS containing
1% RBCs, and left for another 30 min incubation at room temper-
ature. RBCs within samples were then pelleted by centrifugation
at 1400 rpm using a microcentrifuge and supernatants were col-
lected. Twofold serial dilutions were performed using a 96-round
well-bottom plate. Fifty microliter of diluted virus (FLU) at a con-
centration of 80 HAU/ml was then added to each dilution of sera
and incubated for 30 min at room temperature. PBS containing 1%
RBCs was then added to each well and incubated at 4°C. Results
were analyzed 24 h later and neutralizing antibodies in each dilu-
tion was determined by the presence of a pellet of RBCs at the
bottom of the wells.
STATISTICAL ANALYSIS
Results were expressed as mean± SEM. Statistical significance
among samples was calculated using an unpaired Student’s t -test.
P values<0.05 were considered statistically significant.
RESULTS
ANTIBODY RESPONSES INDUCED BY γ-SFV
Avirulent SFV causes asymptomatic infection characterized by
high-titer viremia in adult mice (20, 21), and effective viral clear-
ance has been attributed to rapid antibody responses generated
by the host (22). Interestingly, primary cytotoxic T cell responses
have been shown to be associated with MHC-I haplotype and
restricted to H-2k haplotype expressing mice (23). Particularly,
C57/B6 mice (H-2b haplotype) have been classified as cytotoxic
T cell non-responders and therefore were used in the study. To
confirm that the γ-SFV vaccination strategies used in this study
can generate effective antibody responses, serum SFV-specific IgG
levels were measured 20 days post-infection with live SFV (107
PFU/mouse) or vaccination with variable doses of γ-SFV (106, 107,
or 108 PFU equivalent/mouse). Our data illustrate that vaccination
with γ-SFV induces high levels of SFV-specific IgG in the serum
of vaccinated mice in a dose-dependent manner (Figure 1A).
To determine if the detected antibody responses are protective,
mice were vaccinated withγ-SFV (107 equivalent PFU/mouse) and
challenged 21 days later with live SFV (107 PFU/mouse). Twenty-
four hours post-challenge, serum samples were tested for virus
infectivity by plaque assay. No viral infectivity was detected in all
serum samples from previously vaccinated mice in contrast to the
high viremia observed in un-vaccinated control mice following a
challenge with live SFV (Figure 1B).
It has been previously shown that live SFV infection induces
IFN-I and as a consequence promotes Th1 antibody isotype
switching (20). Considering the inability of γ-SFV to induce
detectable levels of IFN-I (13, 15), the level of IgG isotypes induced
by live SFV vs. γ-SFV was investigated. Mice were infected with
SFV (107 PFU/mouse) or vaccinated with γ-SFV (107 equivalent
PFU/mouse) and serum SFV-specific IgG1 and IgG2c levels were
measured over a time course. Both IgG1 and IgG2c levels appeared
to be lower following vaccination with γ-SFV in comparison to
SFV (Figures 2A,B).
THE EFFECT OF CO-ADMINISTRATION OF γ-FLU AND γ-SFV ON
SFV-SPECIFIC ANTIBODY RESPONSES
Considering the potent IFN-I responses induced by γ-FLU
(13, 14), we investigated the effect of γ-FLU and γ-SFV co-
administration on SFV-specific antibody responses. Mice were co-
injected with γ-SFV (107 PFU equivalent/mouse) and γ-FLU (104
or 105 equivalent TCID50/mouse) and serum SFV-specific IgG
levels were measured at day 20 post-vaccination. Our data illus-
trate the significant enhancement (~six-folds) of SFV-specific IgG
levels in mice co-injected with both γ-SFV and γ-FLU compared
to mice vaccinated with γ-SFV alone (p< 0.05) (Figures 3A,B).
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FIGURE 2 | Immunization with γ-SFV promotes lower antibody levels
compared to SFV. Mice were injected i.v. with SFV (107 PFU) or γ-SFV (107
PFU equivalent/mouse). Serum SFV-specific IgG1 (A) and IgG2c (B) levels
were measured at 3, 6, 12, and 20 days post-immunization by direct ELISA
at a serum dilution of 1/200. Sera from naive mice served as negative
controls (c). Results are presented as mean±SEM (n=3), **p<0.01.
In addition, we investigated the kinetics of SFV-specific antibody
responses post co-administration of γ-SFV and γ-FLU. Similarly,
our data illustrate the consistent enhancement of SFV-specific
antibody responses at all tested time points (p< 0.05) (Figure 3C).
To determine whether enhancement of SFV-specific antibody
responses mediated by co-administration of γ-FLU coincides with
enhanced SFV neutralization, serial dilutions of the immune sera
were tested for their ability to neutralize 100 PFU of live SFV
in vitro using a Vero cells based plaque-inhibition assay. Our results
clearly illustrate that while immune sera from γ-SFV alone vac-
cinated mice have high neutralization activity at 1/100 dilution,
this neutralization activity decreased remarkably with every serial
dilution to reach ~10% activity at 1/800 serial dilution. In con-
trast, immune sera from γ-SFV and γ-FLU co-vaccinated mice
show significantly higher neutralization values for all tested sera
dilutions when compared to sera from γ-SFV alone vaccinated
mice (Figure 3D).
Next, we investigated the effect of γ-FLU and γ-SFV co-
administration on SFV-specific IgG2c and IgG1 levels and whether
co-vaccination may promote a particular IgG isotype. Our data
illustrates that co-administration of γ-FLU and γ-SFV resulted in
significantly enhanced IgG2c levels compared to vaccination with
γ-SFV alone (p< 0.01). However, co-vaccination did not lead to
significant enhancement in IgG1 responses as the detected SFV-
specific IgG1 levels appeared similar in both vaccinated groups
(Figures 4A,B).
THE EFFECT OF CO-VACCINATION ON FLU-SPECIFIC ANTIBODY
RESPONSES
Vaccination with γ-FLU has been shown to elicit homotypic neu-
tralizing antibody responses (10, 11). To determine whether the
co-administration of γ-FLU and γ-SFV affects the host’s ability
to generate effective FLU-specific humoral responses, we investi-
gated FLU-specific IgG responses at day 20 post-vaccination. Our
data indicates that co-vaccination did not suppress the induction
of FLU-specific IgG responses induced by γ-FLU (Figure 5A). We
have also tested the neutralizing efficacy of FLU-specific antibodies
using HA inhibition assay and our data illustrated that the hemag-
glutinating activity of 80 HAU of A/PR8 was inhibited at similar
levels by immune sera from mice vaccinated with γ-FLU alone or
mice co-vaccinated with γ-FLU and γ-SFV (Figure 5B).
THE EFFECT OF AN IFN-I INDUCING ADJUVANT ON THE
IMMUNOGENICITY OF γ-SFV
In line with the common approaches used for adjuvant design, the
adjuvant activity of γ-FLU is expected to be related to its ability to
induce potent IFN-I responses and the associated IFN-I-mediated
partial lymphocyte activation (13). To illustrate the effect of an
IFN-I inducing adjuvant on the immunogenicity of γ-SFV, we
evaluated the effect of poly(I:C) and γ-SFV co-administration
on SFV-specific antibody responses. The ability of poly(I:C) to
induce IFN-I and its potential use as an adjuvant to enhance
humoral responses toward poorly immunogenic proteins has been
well-documented (4, 7, 24). Therefore, mice were vaccinated with
γ-SFV with or without co-injection of poly(I:C) and total SFV-
specific IgG levels in the immune sera were analyzed at days 3, 6,
12, and 20 post-vaccination. Our data illustrate that co-injection
of poly(I:C) and γ-SFV resulted in a significant enhancement in
the level of SFV-specific IgG titers in the serum at all time points
compared to the injection of γ-SFV alone (Figure 6).
DISCUSSION
There has always been an increased demand for safe and effective
vaccines to reduce the morbidity and mortality associated with
particular viral infections. Non-living antigens are often employed
in vaccine strategies and many are poor immunogens (2). We have
reported previously the efficacy of γ-FLU to generate protective
immunity upon homotypic and heterosubtypic influenza A virus
challenges (10, 25). In addition, we have demonstrated the ability
of the γ-FLU vaccine to induce potent IFN-I responses and the
associated partial systemic lymphocyte activation (13, 14). It has
been illustrated previously that IFN-I plays a very influential role
in the development of B lymphocytes and consequently antibody
production (26, 27). In addition, we have reported that γ-SFV, in
contrast to live SFV, does not induce detectable levels of IFN-I (13,
15). Therefore, we used γ-SFV vaccine as an experimental model
to test the adjuvant activity of γ-FLU.
In general, adjuvants are often used to achieve qualita-
tive/quantitative differences in the immune responses that may
include increasing the speed of an immunological response, which
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FIGURE 3 | Co-administration of γ-FLU and γ-SFV enhances SFV-specific
antibody responses. Mice were injected i.v. with a single dose of γ-SFV (107
PFU equivalent/mouse) or co-injected with various doses of γ-FLU (104, 105
TCID50 equivalent/mouse). (A) Serum SFV-specific IgG concentrations
20 days post-vaccination were analyzed at twofold sera dilutions by direct
ELISA and serum from naive mice served as the negative control (naïve).
(B) Folds increase in SFV-specific IgG antibody titers based on the absorbent
value of 0.5 for the tested serum dilutions (A). (C) Serum SFV-specific IgG
levels were analyzed by direct ELISA using a serum dilution of 1/800 at 3, 6,
12, and 20 days post-vaccination. (D) Neutralization of SFV by the immune
sera collected at day 20 post-vaccination as determined by plaque reduction
assay. Data represent mean±SEM (n=3), *p<0.05, **p<0.01.
FIGURE 4 | Co-administration of γ-FLU and γ-SFV enhances
SFV-specific IgG2c responses. Mice were injected i.v. with a single dose
of γ-SFV (107 PFU equivalent/mouse) or co-injected with various doses of
γ-FLU (104, 105 TCID50 equivalent/mouse). SFV-specific IgG1 (A) and IgG2c
(B) levels in the serum at day 20 post-vaccination were analyzed by direct
ELISA using a serum dilution of 1/200. Sera from γ-FLU vaccinated mice
served as negative controls. Data represent mean±SEM (n= 3) **p<0.01.
is important especially during pandemic outbreaks (28, 29). Adju-
vants have also been employed to promote specific types of immu-
nity, which may not be efficiently generated by the non-adjuvanted
antigens, i.e., Th1 vs. Th2 cells, CD8+ vs. CD4+ cells, and specific
types of antibody isotypes (2). Our data clearly show that co-
administration of γ-SFV with γ-FLU amplified SFV-specific IgG
levels with an overall enhancement of ~six-folds. The enhanced
titers observed at day 6 post co-vaccination were equal to the
titers detected at day 20 following vaccination with γ-SFV alone.
Thus, confirming an earlier induction and amplification of SFV
humoral responses. We have also shown this enhancement to be
associated with increased efficiency in virus neutralization. Fur-
thermore, our data illustrate thatγ-FLU promotes enhancement of
type-1 antibody response to co-administered γ-SFV, as illustrated
by the significant increase in IgG2c but not IgG1. This outcome is
commonly desired within vaccine development due to the compe-
tent functions of IgG2a during antigen clearance relative to IgG1
(30–32).
In line with the many approaches used for adjuvant design,
IFN-I responses induced by γ-FLU may have played an impor-
tant role in the observed adjuvant activity of γ-FLU. To evaluate
the role of IFN-I, the adjuvant activity of Poly IC on anti-
body responses to γ-SFV was investigated. The enhancement of
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FIGURE 5 |The effect of co-vaccination on FLU-specific antibody
responses. (A) Mice were injected i.v. with γ-FLU (104 or 105 TCID50
equivalent/mouse) or co-injected with γ-SFV(107 PFU equivalent/mouse)
and serum FLU-specific IgG concentrations were analyzed at day 20
post-vaccination by direct ELISA using a serum dilution of 1/200. Sera from
γ-SFV injected mice served as negative controls. (B) HA inhibition assay
showing dilution of the immune sera capable of inhibiting the
hemagglutinating activity of 80 HAU of A/PR8. Results are presented as
mean±SEM (n=3).
humoral responses against poorly immunogenic proteins using
Poly I:C is well-documented (4, 7, 24). Poly IC, is a synthetic ana-
log of dsRNA, which is commonly used to stimulate TLR3 and
MDA-5 to induce IFN-I and other Th1 priming cytokines such as
IL-12 (8, 33, 34). Consistent with previous reports, our data show
that co-immunization with Poly IC and γ-SFV resulted in signifi-
cantly enhanced SFV-specific IgG titers relative to titers observed
following vaccination with γ-SFV alone. While this suggest a pos-
sible role of IFN-I, more work will be conducted to analyze the
underline mechanisms for the adjuvant activity of γ-FLU.
The ultimate goal of using γ-FLU as an adjuvant is to exploit the
efficacy of the γ-FLU-mediated immune response toward com-
bined vaccines, in addition to conferring protection against the
influenza virus. Our results show that co-administration of γ-FLU
and γ-SFV did not affect the titers of FLU-specific IgG and did not
affect the neutralizing activity of FLU-specific antibodies. There-
fore, humoral responses generated against FLU antigens were not
hindered when a second vaccine is present in the environment.
Overall, this study is a proof-of-concept illustrating that γ-FLU, a
whole virus killed influenza vaccine, can potentially be employed
as an adjuvant to increase the quality and magnitude of immune
FIGURE 6 | Co-administration of Poly(I:C) and γ-SFV enhances
SFV-specific IgG levels. Mice were vaccinated i.v. with γ-SFV (107 PFU
equivalent/mouse) or co-injected with poly (I:C) (150µg). Total SFV-specific
IgG levels in the serum were analyzed at day 3, 6, 12, and 20
post-vaccination using direct ELISA using a serum dilution of 1/200. Sera
from naive mice served as negative controls. Results are presented as
mean±SEM (n=3) (*) denotes statistical significance, **p<0.01,
***p<0.001.
responses toward co-administered less immunogenic vaccines.
Future studies will investigate the clinical relevance of the γ-FLU-
based combined vaccination strategy, particularly in relation to
intranasal and intramuscular routes of administration. Future
studies will also examine the effect of co-administered vaccines
on the ability of γ-FLU to induce cross-protective immunity.
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